{"entity":{"id":"quanta-therapeutics","kind":"company","name":"Quanta Therapeutics","aka":[],"tldr":"Quanta Therapeutics develops oral multi-KRAS inhibitors biased to G12D (QTX3034) and G12V (QTX3544), with responses in pancreatic, colorectal, and endometrial cancer.","summary":"Quanta Therapeutics, based in South San Francisco, develops oral multi-KRAS inhibitors biased towards G12D, QTX3034, and G12V, QTX3544, with responses reported in pancreatic, colorectal and endometrial cancer. Phase 1 data in October 2025 showed confirmed responses for QTX3034 alone and with cetuximab in colorectal, pancreatic and endometrial cancer, and preclinical data in March 2026 showed both compounds retain activity against resistance mechanisms acquired on the pan-RAS inhibitor daraxonrasib. OnCo links it to pancreatic, colorectal and endometrial cancer, to KRAS and RAS inhibitors, to KRAS as a target and the MAPK pathway, to daraxonrasib and to the bottleneck of undruggable drivers. Whether mutation-biased inhibitors or pan-RAS drugs win on the balance of efficacy and tolerability is the open question. Daraxonrasib has its own page.","asOf":"2026-09-04","links":[{"label":"March 2026 release","url":"https://www.quantatx.com/news/030526/"}],"tags":[],"related":[],"cancers":["pancreatic","colorectal","endometrial"],"sections":["targeted-therapy"],"technologies":["kras-inhibitors"],"targets":["kras"],"drugs":["daraxonrasib"],"companies":[],"institutions":[],"pathways":["ras-mapk"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.quantatx.com","investors":[],"funding":[]},"route":"/companies/quanta-therapeutics/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"drug":[{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/"}],"pathway":[{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/"}],"bottleneck":[{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/"}],"idea":[{"id":"idea-bio1-pan-ras-covalent-g12d","kind":"idea","name":"Covalent chemistry for the RAS mutations that still have no drug","route":"/ideas/idea-bio1-pan-ras-covalent-g12d/"}]}}